Ekso Bionics’ (EKSO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock.

EKSO has been the topic of a number of other reports. StockNews.com initiated coverage on Ekso Bionics in a research report on Tuesday. They issued a “hold” rating on the stock. Lake Street Capital cut their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th.

Ekso Bionics Stock Up 6.3 %

Shares of NASDAQ EKSO opened at $0.69 on Tuesday. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The company has a market cap of $15.20 million, a price-to-earnings ratio of -1.06 and a beta of 1.47. Ekso Bionics has a 12-month low of $0.50 and a 12-month high of $2.50. The firm’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.95.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same quarter in the previous year, the company posted ($0.24) earnings per share. On average, research analysts expect that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.